Bafrekalant is a diazabicyclic substituted imidazo[l,2-a]pyrimidine-derivative. Bafrekalant has the potential for the research of breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnea and snoring (extracted from patent WO2018228907A1).
[1]. Martina Delbeck, et al. Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders. Patent WO2018228907A1.